Company Overview: Benitec

Industry News

17 May

Benitec Biopharma to Host Corporate Update Conference Call

Conference Call and Live Audio Webcast Scheduled for Wednesday, 25 May 2016 at 8:00am AEST / Tuesday, 24 May at 6:00pm EDT SYDNEY, May 17, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that the Company will host a conference call and live audio...

Read more

25 Apr

Benitec to present at the ASGCT 2016 Annual Meeting

SYDNEY, April 25, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or ‘expressed RNAi’, today announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy...

Read more

8 Mar

Benitec’s Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo

SYDNEY, March 8, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that BB-HB-331, a DNA-directed RNA interference (ddRNAi) therapy targeting the hepatitis B virus (HBV), demonstrates robust and durable suppression of HBV in vivo following a single administration. Benitec’s ddRNAi technology is a...

Read more

26 Jul

Benitec Biopharma Ltd

Benitec Biopharma holds the dominant global patent position for expressed RNA interference (also called DNA-directed RNAi (ddRNAi)), placing the company in a commanding position for human therapies associated with specific genes and genetic disorders. The use of shRNA for use in humans falls under our patent estate. Our patented technology, ddRNAi,...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address